Applied Genetic Technologies Corp AGTC Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.39 unchanged at close Dec 1
Last close · Previous close $0.39
- Market cap
- $26.62MAt the Dec 1 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.42Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.39down $0.02, 4.23%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.39Nov 30
- Volume0.00Dec 1 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.06MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Dec 1 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | AGTC |
|---|---|
| Short term | |
| 1M | AGTC: down 4.2% |
| 3M | AGTC: down 1.8% |
| YTD | AGTC: down 79.3% |
| 1Y | AGTC: down 81.1% |
| Long term | |
| 3Y | AGTC: down 85.6% −47.6% a year |
| 5Y | AGTC: down 89.6% −36.5% a year |
$10,000 invested in AGTC 5 years ago (Dec 1, 2017) would be worth about $1,036 at the close on , with dividends reinvested.
| Period | AGTC |
|---|---|
| Short term | |
| 1M | AGTC: down 4.2% |
| 3M | AGTC: down 1.8% |
| YTD | AGTC: down 79.3% |
| 1Y | AGTC: down 81.1% |
| Long term | |
| 3Y | AGTC: down 85.6% −47.6% a year |
| 5Y | AGTC: down 89.6% −36.5% a year |
$10,000 invested in AGTC 5 years ago (Dec 1, 2017) would be worth about $1,036 at the close on , not counting dividends.
All-time high
$31.69
Closing high on . Now 98.8% below that record.
Split-adjusted daily closes since Mar 27, 2014.
Stock splits
AGTC hasn’t split since its price history begins in 2014.
Valuation
The Dec 1 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2022). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$1.42 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 81.9×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 1.5×Book value as of Sep 30, 2022
Price relative to accounting equity (book value) per share on the Sep 30, 2022 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −252.28%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $9.61MAt the Dec 1 close
What it would cost to buy the whole business: the market cap at the Dec 1 close, plus debt, minus cash and short-term investments from the Sep 30, 2022 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own AGTC DCF in Excel. Value Applied Genetic Technologies with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY23, the quarter ended Sep 30, 2022. “Last 12 months” means the four quarters from Oct 1, 2021 to Sep 30, 2022, and balance-sheet figures are as of Sep 30, 2022.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $325.00Kdown 35.0%
- Net income
- −$70.23M
- Diluted EPS
- −$1.42
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY21 (Dec 31, 2020) | $0.00 | −$15.46M | −$0.60 |
| Q3 FY21 (Mar 31, 2021) | $0.00 | −$14.85M | −$0.40 |
| Q4 FY21 (Jun 30, 2021) | $500.00K | −$12.14M | −$0.22 |
| Q1 FY22 (Sep 30, 2021) | $0.00 | −$17.12M | −$0.40 |
| Q2 FY22 (Dec 31, 2021) | $0.00 | −$19.14M | −$0.45 |
| Q3 FY22 (Mar 31, 2022) | $0.00 | −$14.29M | −$0.33 |
| Q4 FY22 (Jun 30, 2022) | $325.00K | −$18.39M | −$0.36 |
| Q1 FY23 (Sep 30, 2022) | $0.00 | −$18.41M | −$0.28 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Jun 30, 2021) | $500.00K | −$57.83M | −$1.77 |
| FY22 (Jun 30, 2022) | $325.00K | −$68.94M | −$1.53 |
Margins
- Gross 100.0%
- Operating −20,644.3%
- Net −21,610.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$67.16MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$65.85MLast 12 months
- Capital spending$1.31MLast 12 months
- −20,663.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $18.29MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $44.89MAs of Sep 30, 2022
Cash plus short- and long-term marketable securities on the Sep 30, 2022 balance sheet.
- Total debt$20.15MAs of Sep 30, 2022
- Net cash$24.74MAs of Sep 30, 2022
- 1.40As of Sep 30, 2022
Current assets divided by current liabilities on the Sep 30, 2022 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.14As of Sep 30, 2022
Total debt divided by shareholders’ equity on the Sep 30, 2022 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −192.9%Last 12 months
Over the last 12 months, Applied Genetic Technologies lost money: its net loss was 192.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −92.5%Last 12 months
Over the last 12 months, Applied Genetic Technologies’s net loss was 92.5% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Applied Genetic Technologies Corp
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The companys lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics. The company was founded in 1999 and is headquartered in Alachua, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AGTC news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AGTC stock FAQ
What is AGTC stock’s price today?
Applied Genetic Technologies (AGTC) traded at $0.39 at the close on , unchanged from the previous close of $0.39.
If you invested $1,000 in AGTC 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in AGTC on would be worth about $104 at the close on , a total return of −89.6%. The same $1,000 would be worth $189 if invested one year ago. Past performance doesn’t predict future returns.
What is Applied Genetic Technologies’s market cap?
Applied Genetic Technologies’s market capitalization is about $26.6 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.39 (how market cap works). Applied Genetic Technologies reported 67.63M shares outstanding at the end of its latest quarter ().
What is AGTC’s P/E ratio?
AGTC’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.42).
How much revenue does Applied Genetic Technologies make?
Applied Genetic Technologies reported $325.0 thousand of revenue over the four quarters to , down 35.0% from the twelve months before. In its latest quarter (Q1 FY23, ended ) revenue was $0.0 thousand.
Is Applied Genetic Technologies profitable?
Not over the four quarters to . Applied Genetic Technologies reported a net loss of $70.2 million across those four quarters on $325.0 thousand of revenue.
What are AGTC’s earnings per share?
AGTC’s diluted earnings per share were −$1.42 over the four quarters to , compared with −$1.62 in the twelve months before. The latest quarter (Q1 FY23) brought −$0.28 per share, against −$0.40 a year earlier (how EPS works).
Does AGTC pay a dividend?
Applied Genetic Technologies hasn’t paid a dividend in the last twelve months.
What is AGTC’s all-time high?
AGTC’s highest closing price was $31.69 on , adjusted for stock splits. At $0.39 at the close on , it is 98.8% below that record.
Has AGTC stock ever split?
No. AGTC hasn’t split since its price history begins in 2014.
How has AGTC stock performed?
Including dividends and measured to the close on , AGTC has returned −79.3% so far this year and −81.1% over the past year, and −89.6% over five years (−36.5% a year). Past performance doesn’t predict future returns.
What sector and industry is Applied Genetic Technologies in?
Applied Genetic Technologies is in the Healthcare sector and the Biotechnology industry, and is headquartered in Florida, USA.
What exchange does AGTC trade on?
Applied Genetic Technologies trades on the Nasdaq under the ticker symbol AGTC. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.